Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114938 | 0.82 | KDM4E (0.63) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL5433655 | 0.82 | NPSR1 (0.46) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL1417913 | 0.81 | KDM4E (0.81) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL16296266 | 0.80 | KDM4E (0.69) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL19659065 | 0.80 | KDM4E (0.56) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL10278987 | 0.79 | KDM4E (0.59) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL4957306 | 0.79 | KDM4E (0.59) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL5870445 | 0.78 | KDM4E (0.58) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL10570426 | 0.78 | KDM4E (1.00) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL5185328 | 0.78 | KDM4E (0.77) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| CN-119798159-A | PAPD5 inhibitors and methods of use thereof | 儿童医学中心公司 | 2025-04-11 | — | — | CN | disclosed |
| US-12012414-B1 | Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors | King Faisal University (SA) | 2024-06-18 | — | — | US | disclosed |
| CN-114106000-B | Imidazo [4,5-d ] pyrimidinone tricyclic derivative and antitumor application thereof | 中国科学院新疆理化技术研究所 | 2023-11-24 | — | — | CN | disclosed |
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-116507337-A | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4192836-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-09-28 | — | — | US | disclosed |
| WO-2005037257-A2 | NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| WO-1992013451-A1 | IMIDAZOLE PESTICIDES | SCHERING AGROCHEMICALS LIMITED (GB) | 1992-08-20 | — | — | WO | disclosed |
| EP-0183848-B1 | POLYAZAHETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4918074-A | CALCIUM ANTAGONISTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-04-17 | — | — | US | disclosed |
| EP-0252682-A2 | Tetrazines | MAY & BAKER LIMITED (GB) | 1988-01-13 | — | — | EP | disclosed |
| EP-0217142-A2 | A polyazaheterocyclic compound | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1987-04-08 | — | — | EP | disclosed |
| EP-0183848-A1 | POLYAZAHETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1986-06-11 | — | — | EP | disclosed |
| US-4236005-A | ANTIANXIETY | AMERICAN CYANAMID COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4178449-A | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | NAT1, TPMT, ACAT1 | KDM4E 1335/4885SMN1; SMN2 831/4885ALDH1A1 90/4885 |
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | KDM4E 4779/4885SMN1; SMN2 1169/4885ALDH1A1 1354/4885 |
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | POT1, PARP15, TERT | KDM4E 2610/4885SMN1; SMN2 2702/4885ALDH1A1 2425/4885 |
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ATR, CHEK1, CHEK2 | KDM4E 2648/4885SMN1; SMN2 1298/4885ALDH1A1 4462/4885 |
| US-12012414-B1 | Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors | CDK2, CSNK1A1, CSNK2A1 | KDM4E 2122/4885SMN1; SMN2 1927/4885ALDH1A1 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.